Drug use for neuropsychic disorders in patients with Parkinson's disease

E. Martignoni, O. Leoni, M. Cosentino, E. Corengia, C. Fundarò, C. Oria, D. Michielotto, C. Pacchetti, F. Mancini, S. Lecchini, G. M. Frigo, G. Nappi

Research output: Contribution to journalArticlepeer-review

Abstract

The neuropsychic co-morbidity is more frequent in Parkinson's disease than in other non-neurological disorders with similar disability. Depression is described in 45% of patients with Parkinson's disease and anxiety in 40%. Depression and anxiety are not necessarily associated. Psychotic disorders are often correlated to therapy and are described in 10%-15% of cases. The present pharmaco-epidemiological study on ambulatory patients has verified the prescription of drugs for the following neuropsychic indications (ICD-9-CM): anxiety (300.0), depression (311), hallucination (780.1 ), sleep disorders (780.5). One hundred thirty-six patients were enrolled, aged between 38 and 87 years (mean 68.6) and with duration of illness between 1 and 24 years (mean 6.7). 50.7% of patients have taken drugs for at least one of these indications, and exactly: 19.1 % for anxiety, 16.0% for depression, 7.3% for hallucination, 20.6% for sleep disorders. The intake of drugs for anxiety is more prevalent in females (30.6% vs. 6.2% in males, P <0.0003). Duration of Parkinson's disease is longer in depressed patients (8.8 ±5.0 years vs. 6.4 ±4.3 years, P <0.02). Hallucinations are more often described in elderly (74.2 ±10.7 years vs. 68.1 ±9.7 years, P <0.05). The duration of Parkinson's disease is longer in treated patients for anxiety, depression and hallucination than nontreated patients (8.0 ±5.1 years vs. 6.0 ±4.0 years, P <0.02). None of this variable is significant in treated patients with sleep disorder. In anxiety seven different drugs are used (six belong to anxiety category ATC N05B, one to hypnotic and sedative category N05C), ten drugs in depression (nine belong to antidepressant category N06A, one to antidepressant and psychoanaleptic category N06C), five drugs in hallucination (antipsychotic category N05A). Among antipsychotic drugs clozapine is administered in 7 out of 11. Category, indication and employment of neuropsychic drugs can support the evaluation and nursing of psychiatric co-morbidity in Parkinson's disease.

Original languageEnglish
Pages (from-to)267
Number of pages1
JournalItalian Journal of Neurological Sciences
Volume20
Issue number4
Publication statusPublished - 1999

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Fingerprint Dive into the research topics of 'Drug use for neuropsychic disorders in patients with Parkinson's disease'. Together they form a unique fingerprint.

Cite this